J. Safra Sarasin Holding Ag Vaxcyte, Inc. Transaction History
J. Safra Sarasin Holding Ag
- $5.52 Trillion
- Q1 2025
A detailed history of J. Safra Sarasin Holding Ag transactions in Vaxcyte, Inc. stock. As of the latest transaction made, J. Safra Sarasin Holding Ag holds 12,436 shares of PCVX stock, worth $426,306. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,436Holding current value
$426,306% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
353Shares Held
124MCall Options Held
539KPut Options Held
253K-
Vanguard Group Inc Valley Forge, PA12MShares$413 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$363 Million0.46% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$341 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$298 Million11.52% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.21MShares$213 Million0.11% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.03B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...